Showing 3141-3150 of 3315 results for "".
- I-PEN Osmolarity System Now Available in Brazil Through Partnership with DryComhttps://modernod.com/news/i-pen-osmolarity-system-now-available-in-brazil-through-partnership-with-drycom/2476420/The I-PEN is the world’s first, point-of-care, electronic diagnostic testing device to detect and indirectly measure the tear film osmolarity levels associated with marginal, mild, moderate and severe dry eye disease. The I-PEN Osmolarity System, used in conjunction with the I-PEN Osmolarity Sing
- User-Friendly Visual-Acuity Chart Shows Good Agreement With Existing Chartshttps://modernod.com/news/user-friendly-visual-acuity-chart-shows-good-agreement-with-existing-charts/2476405/The Runge near-vision card is user-friendly and shows good agreement with the Early Treatment Diabetic Retinopathy Study (ETDRS) and Snellen visual-acuity charts, researchers report, according to Reuters Health. “The Runge nea
- VSP Global Names Steve Baker President of VSP Ventureshttps://modernod.com/news/vsp-global-names-steve-baker-president-of-vsp-ventures/2476398/VSP Global has announced the appointment of Steve Baker, president of Eyefinity, to lead the newly-established VSP Ventures, according to a report in VisionMonday. “Steve’
- 5% People Tested Positive at Free Initial Screenings for Glaucoma at Saifee Hospitalhttps://modernod.com/news/5-people-tested-positive-at-free-initial-screenings-for-glaucoma-at-saifee-hospital/2476400/Saifee Hospital, one of Mumbai’s leading multi-specialty hospitals, conducted almost 400 free eye check-ups for their visitors to observe World Glaucoma Week. The check-ups were conducted throughout the week and more than 20 people were detected to have high
- Aerpio Pharmaceuticals Does Not Meet Primary Endpoint in Phase 2b Study for Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-does-not-meet-primary-endpoint-in-phase-2b-study-for-diabetic-retinopathy/2476386/Aerpio Pharmaceuticals announced topline results from the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). Administration o
- Alcon Acquires Fluid-Based IOL Maker PowerVisionhttps://modernod.com/news/alcon-announces-acquisition-of-powervision/2476387/Alcon announced that it has acquired PowerVision for $285 million plus regulatory and milestone payments starting in 2023. PowerVision’s lens design utilizes the eye’s natural accommodating response to transport fluid in the IOL. While most presbyopia-correcting IOLs use a mult
- Clinical Trials Show Safety and Efficacy of Inveltys for BID Treatment of Postoperative Inflammation and Painhttps://modernod.com/news/clinical-trials-show-safety-and-efficacy-of-kala-pharmaceuticals-inveltys-for-bid-treatment-of-postoperative-inflammation-and-pain/2476380/Kala Pharmaceuticals announced publication of two multicenter, randomized, double-masked, vehicle-controlled clinical trials of Inveltys (loteprednol etabonate ophthalmic suspension 1%) for treatment of inflammation and pain following cataract surgery. Inveltys, which utilizes AMPPLIFY D
- Coburn Technologies Introduces New Spin Coater with Dual-Coating Technology, Velocity 2Dhttps://modernod.com/news/coburn-technologies-introduces-new-spin-coater-with-dual-coating-technology-velocity-2d/2476376/Coburn Technologies has introcued the Velocity 2D, the next generation of the Velocity Automated Spin Coater, now designed with dual-coating technology. Derived from the existing platform of the ground-breaking Velocity automated lens coater, the Velocity 2D now offers labs the ability to
- Q Biomed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression From Washington Universityhttps://modernod.com/news/q-biomed-licenses-novel-biomarker-for-monitoring-glaucoma-severity-and-progression-from-washington-university/2476369/Q BioMed has announced it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. Determining the severity
- Zeiss Receives FDA Clearance for Epithelial Thickness Mapping for CIRRUS HD-OCThttps://modernod.com/news/zeiss-receives-fda-clearance-for-epithelial-thickness-mapping-for-cirrus-hd-oct/2476359/Zeiss announced that it has received FDA 510(k) clearance for the CIRRUS HD-OCT platform, expanding the capabilities of its Anterior Segment Premier Module to include epithelial thickness mapping (ETM). According to refractive specialist John Doane, MD, of Discover Vision Center in Kansas